|
|
Article: Saegis Nearing End Of Phase II While Still Using Series A Cash.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
As the baby boomers age, many will face problems with memory they used to associate with their parents and grandparents.
And Saegis Pharmaceuticals Inc. (formerly David Pharmaceuticals), of Half Moon Bay, Calif., is working to develop drugs to meet the need as millions face the loss of memory and cognition associated with aging.
"The company wasn't founded on a platform technology," said Brent Vaughan, Saegis' director of corporate development. "It was founded on the idea of looking at MCI [mild cognitive impairment] and early Alzheimer's as specific indications separate from Alzheimer's disease and for which specific therapeutics ...